{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:01:59Z","timestamp":1791932519017,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T00:00:00Z","timestamp":1546387200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10792-018-01064-7","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T02:28:11Z","timestamp":1546396091000},"page":"2267-2274","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comparison of fluorescein angiographic findings in type 1 and type 2 retinopathy of prematurity with intravitreal bevacizumab monotherapy and spontaneous regression"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-1947","authenticated-orcid":false,"given":"Asl\u0131","family":"Vural","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilbade Y\u0131ld\u0131z","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail Umut","family":"Onur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcls\u00fcm Oya","family":"Herg\u00fcnsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadime Ulviye","family":"Yi\u011fit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,2]]},"reference":[{"key":"1064_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1091-8531(99)70091-1","volume":"3","author":"PG Stenkuller","year":"1999","unstructured":"Stenkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK et al (1999) Childhood blindness. J AAPOS 3:26\u201332","journal-title":"J AAPOS"},{"key":"1064_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3928\/01913913-20150216-01","volume":"52","author":"MA Klufas","year":"2015","unstructured":"Klufas MA, Chan RV (2015) Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7\u00a0years. J Pediatr Ophthalmol Strabismus 52:77\u201384","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1064_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"WC Wu","year":"2015","unstructured":"Wu WC, Lien R, Liao PJ, Wang NK, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133:391\u2013397","journal-title":"JAMA Ophthalmol"},{"key":"1064_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","volume":"254","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Jiang Y, Bai Y, Wen J, Chen L (2016) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefe\u2019s Arch Clin Exp Ophthalmol 254:31\u201336","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"issue":"6","key":"1064_CR5","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","volume":"10","author":"L Pertl","year":"2015","unstructured":"Pertl L, Steinwender G, Mayer C, Hausberger S, P\u00f6schl EM, Wackernagel W, Wedrich A, El-Shabrawi Y, Haas A (2015) A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLOS ONE 10(6):e0129383","journal-title":"PLOS ONE"},{"key":"1064_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1167\/iovs.13-13429","volume":"55","author":"H Wang","year":"2014","unstructured":"Wang H, Yang Z, Jiang Y, Flannery J, Hammond S, Kafri T, Vemuri SK, Jones B, Hartnett ME (2014) Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity. Investig Ophthalmol Vis Sci 55:737\u2013744","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1064_CR7","first-page":"34557","volume":"14","author":"P Geisen","year":"2008","unstructured":"Geisen P, Peterson LJ, Mariniuk D (2008) Neutralizing anti-body to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 14:34557","journal-title":"Mol Vis"},{"key":"1064_CR8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"1064_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/17469899.2015.1007128","volume":"10","author":"B Lorenz","year":"2015","unstructured":"Lorenz B, Stieger K (2015) Retinopathy of prematurity recent developments in diagnosis and treatment. Expert Rev Ophthalmol 10:167\u2013182","journal-title":"Expert Rev Ophthalmol"},{"issue":"8","key":"1064_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/archophthalmol.2008.1","volume":"126","author":"L Kong","year":"2008","unstructured":"Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chevez-Barrios P (2008) Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 126(8):1161\u20131163","journal-title":"Arch Ophthalmol"},{"key":"1064_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, the BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity: preliminary results of the BEAT-ROP clinical trial. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"1064_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, Mc Melamine PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy\u00a0of prematurity. Br J Ophthalmol 98:507\u2013512","journal-title":"Br J Ophthalmol"},{"key":"1064_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG, Bruch M, Cardone S, Hess D, Johnson RA, Puliafito CA (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28:13\u201318","journal-title":"Retina"},{"key":"1064_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 28:831\u2013838","journal-title":"Retina"},{"key":"1064_CR15","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","volume":"92","author":"S Kusaka","year":"2008","unstructured":"Kusaka S, Shima C, Wada K, Arahori H, Shimojyo H, Sato T, Fujikado T (2008) Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol 92:1450\u20131455","journal-title":"Br J Ophthalmol"},{"key":"1064_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","volume":"33","author":"MA Martinez-Castellanos","year":"2013","unstructured":"Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, Kon-Jara VA, Garcia-Aguirre G, Guerrero-Naranjo JL, Chan RV, Quiroz-Mercado H (2013) Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5\u00a0years of follow-up. Retina 33:329\u2013338","journal-title":"Retina"},{"key":"1064_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz B, Stieger K, Jager M, Mais C, Stieger S, Andrassi-Daida M (2017) Retinal vascular development with 0.312\u00a0mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina 37:97\u2013111","journal-title":"Retina"},{"key":"1064_CR18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clp.2013.02.005","volume":"40","author":"DK Wallace","year":"2013","unstructured":"Wallace DK, Wu KY (2013) Current and future trends in treatment of severe retinopathy of prematurity. Clin Perinatol 40:297\u2013310","journal-title":"Clin Perinatol"},{"key":"1064_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza B, Jonas JB (2013) Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155:1119\u20131124","journal-title":"Am J Ophthalmol"},{"key":"1064_CR20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, Tawansy KA, Mintz-Hittner HA, BEAT-ROP cooperative Group (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132:1327\u20131333","journal-title":"JAMA Ophthalmol"},{"key":"1064_CR21","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/eye.2014.172","volume":"28","author":"Y-H Chen","year":"2014","unstructured":"Chen Y-H, Chen S-N, Lien RI, Shih CP, Chao AN, Chen KJ, Hwang YS, Wang NK, Chen YP et al (2014) Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye 28:1080\u20131087","journal-title":"Eye"},{"key":"1064_CR22","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","volume":"123","author":"HA Mintz-hittner","year":"2016","unstructured":"Mintz-hittner HA, Geloneck MM, Chuang AZ (2016) Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology 123:1845\u20131855","journal-title":"Ophthalmology"},{"key":"1064_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.001","volume":"63","author":"S Selvam","year":"2018","unstructured":"Selvam S, Kumar T, Fruttiger M (2018) Retinal vasculature development in health and disease. Prog Retin Eye Res 63:1\u201319","journal-title":"Prog Retin Eye Res"},{"key":"1064_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","volume":"38","author":"JM Garcia Gonzalez","year":"2018","unstructured":"Garcia Gonzalez JM, Snyder L, Blair M, Rohr A, Shapiro M, Greenwald M (2018) Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity. Retina 38:764\u2013772","journal-title":"Retina"},{"key":"1064_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","volume":"16","author":"MP Blair","year":"2012","unstructured":"Blair MP, Shapiro MJ, Hartnett ME (2012) Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children. J Am Assoc Pediatr Ophthalmol Strabismus 16:234\u2013237","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"1064_CR26","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R (2012) Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 130:1000\u20131006","journal-title":"Arch Ophthalmol"},{"key":"1064_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35:675\u2013680","journal-title":"Retina"},{"key":"1064_CR28","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.ophtha.2016.04.024","volume":"123","author":"M Isaac","year":"2016","unstructured":"Isaac M, Mireskandari K, Tehrani N (2016) Does bevacizumab alter vascularization potential in retinopathy of prematurity? Ophthalmology 123:2042\u20132043","journal-title":"Ophthalmology"},{"key":"1064_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore D, Quinn GE, Molle F, Orazi L, Baldascino A, Ji MH, Sammartino M, Sbaraglia F, Ricci D, Mercuri E (2018) Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 125:218\u2013226","journal-title":"Ophthalmology"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-018-01064-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10792-018-01064-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-018-01064-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T19:26:02Z","timestamp":1577906762000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10792-018-01064-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,2]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1007\/s10792-018-01064-7","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,2]]},"assertion":[{"value":"21 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge, or beliefs) in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (Dr. Sadi Konuk Bakirkoy EAH ethical committee) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. It is a retrospective study; therefore, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants\u2019 parents in the study, as it is routinely done before all invasive procedure.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}